Patients waiting 5-plus hours in the ED before hospital admission face increased mortality risk

Patients waiting more than five hours in the emergency department before being admitted into the hospital face an increased risk of all-cause death within the following 30 days, new research shows.

In fact, there was 1 extra death for every 82 individuals whose inpatient status was delayed 6-8 hours after arriving in the ED, experts reported Tuesday in BMJ. The study included more than 5 million patients treated across England between 2016 and 2018.

Emergency department wait times have declined in the U.S. over the past decade, but millions still go two hours without seeing a provider and COVID-19 has only worsened those statistics. England enacted a four-hour target to discharge, admit or transfer patients to minimize overcrowding, with other countries like Canada and Australia doing the same.

And while about 38% of patients, on average, waited more than four hours before being admitted, the established target appears to be helping patients and may also benefit American EDs. 

“This study confirms that healthcare policymakers should continue to mandate timely admission from the [emergency department] in order to protect patients from hospital-associated harm,” Simon Jones, with the Department of Population health at New York University School of Medicine, and co-authors wrote.

The study included more than 26 million emergency department visits between April 2016 and March 2018, with 5,249,891 admitted to the hospital. More than 433,000 people died within 30 days of admission during the study period.

About 38% of patients, on average, waited longer than the four-hour benchmark. The team noted a statistically significant increase in the death rate for waits exceeding five hours.

In fact, they reported a 10% increase in the standardized mortality rate within 30 days for inpatients sitting in the ED between 8-12 hours compared to those who left within six.

The group noted that 30-day mortality doesn’t account for factors such as increases in patient morbidity or worse patient experiences and the observational nature of their research can’t establish cause and effect. But keeping patients waiting, they added, is never beneficial.

“Delays to inpatient admission from any cause are of no value to the patient and may also impede timely care for new ED arrivals,” the authors concluded.

You can read the full study here.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.